首页> 外国专利> TREATMENT OF MULTIPLE SCLEROSIS IN COMBINATION WITH LAQUINIMOD AND GLATIRAMER ACETATE

TREATMENT OF MULTIPLE SCLEROSIS IN COMBINATION WITH LAQUINIMOD AND GLATIRAMER ACETATE

机译：拉米尼莫德和醋酸格拉默联合治疗多发性硬化症

页面导航

摘要
著录项
相似文献

摘要

PROBLEM TO BE SOLVED: To provide pharmaceutical compositions for treating patients suffering from multiple sclerosis or patients presenting a clinically isolated syndrome.SOLUTION: A pharmaceutical composition having 0.6 mg of laquinimod is prepared as an add-on therapy to a certain amount of glatiramer acetate or as a combination therapy with the same, wherein the amount of laquinimod and the amount of glatiramer acetate are more effective for treating a human patient when being taken in together, as compared with when each drug is administered independently in the amount. Preferably, the laquinimod is laquinimod sodium, and preferably, the pharmaceutical composition is prepared for periodical administration.SELECTED DRAWING: None

机译：解决的问题：提供用于治疗患有多发性硬化症的患者或表现出临床分离的综合症的患者的药物组合物。解决方案：制备具有0.6 mg拉喹莫德的药物组合物作为一定量醋酸格拉替雷或作为组合疗法，其中拉喹莫德的量和醋酸格拉替雷的量与一起单独给药时相比，在一起服用时更能有效地治疗人类患者。优选地，拉喹莫德是拉喹莫德钠，并且优选地，该药物组合物被制备用于定期给药。

著录项

公开/公告号JP2017081930A

专利类型
公开/公告日2017-05-18

原文格式PDF
申请/专利权人 TEVA PHARMACEUTICAL INDUSTRIES LTD;
展开▼

申请/专利号JP2016230818
发明设计人 YOSSI GILGUN;NORA TARCIC;
展开▼

申请日2016-11-29
分类号A61K31/4704;A61K38;A61K9/08;A61K9/12;A61K9/14;A61K9/20;A61K9/48;A61K9/72;A61K45;A61K47/10;A61K47/12;A61K47/14;A61K47/18;A61K47/26;A61K47/36;A61K47/38;A61P25;
国家 JP
入库时间 2022-08-21 14:01:38

相似文献

专利
外文文献
中文文献